Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-087230
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 1
---

stockholder engagement and perspectives. However, we firmly believe that Zevra’s nominees, who have helped the Company take decisive action over the past two years to drive significant stockholder value, are the right directors to continue
driving our progress towards becoming a leading rare disease therapeutics company.

Importantly, we do not want this to become a distraction for you. The
best way to mitigate noise such as this is to continue to execute on our goals and remain focused on our pursuit towards making life-changing therapies available to patients suffering from rare diseases.

As I’ve mentioned in previous emails, it is incredibly important that we continue to speak with one voice and refrain from speculating on this news.
Consistent with our company policy, in the event you are contacted by a member of the media, the investment community, or any other party, we ask that you simply respond that you are not authorized to comment on the matter, and immediately share
their name and contact information with Nichol, LaDuane, Rahsaan and/or myself. I’d also like to remind you of our employee social media policy, which I’ve linked here.

Thank you for your commitment to Zevra and the patients we serve.

Sincerely,

Neil F. McFarlane

President and Chief Executive Officer

Zevra Therapeutics, Inc.
(NASDAQ: ZVRA)

O: | F:

www.zevra.com| nmcfarlane@zevra.com

Additional Information and Where to Find It

Zevra has filed with the SEC a definitive proxy statement on Schedule 14A, containing a form of WHITE proxy card, with respect to its solicitation of
proxies for the 2025 Annual Meeting of Stockholders.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT
(INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY ZEVRA, AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED BY ZEVRA WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION.

Investors and security holders may obtain copies of these documents and other documents filed with the SEC by Zevra free of charge through the website
maintained by the SEC at . Copies of the documents filed by Zevra are also available free of charge by accessing Zevra’s investor relations website at .

Participants in the Solicitation